A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Our INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex, or IFC, and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received a broad range of regulatory approvals and certification, including but not limited to FDA approval in the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 234M | 234M | 201M | 187M | 188M | 160M |
| Net Income | -16M | -16M | -21M | -37M | -43M | -54M |
| EPS | $-0.08 | $-0.08 | $-0.11 | $-0.21 | $-0.24 | $-0.32 |
| Free Cash Flow | 1.1M | 1.1M | 8.5M | -48M | -28M | -35M |
| ROIC | -3.7% | -13.8% | -17.3% | -33.3% | -52.6% | -39.0% |
| Gross Margin | 48.0% | 48.0% | 49.4% | 46.3% | 46.2% | 42.2% |
| Debt/Equity | 2.18 | 2.18 | 2.09 | 2.20 | 2.12 | 1.21 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -8.7M | -8.7M | -14M | -30M | -34M | -49M |
| Operating Margin | -3.7% | -3.7% | -7.1% | -16.1% | -18.1% | -30.7% |
| ROE | -24.3% | -26.0% | -37.3% | -71.2% | -63.3% | -64.3% |
| Shares Outstanding | 195M | 195M | 190M | 179M | 178M | 170M |
CERUS CORP passes 0 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 348.6x vs a median of 34.8x. The company's 5-year average gross margin is 46.4%.
CERUS CORP (CERS) has a 5-year average return on invested capital (ROIC) of -31.2%. This is below average and may indicate limited pricing power.
CERUS CORP (CERS) has a market capitalization of $393M. It is classified as a small-cap stock.
CERUS CORP (CERS) does not currently pay a regular dividend.
CERUS CORP (CERS) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
CERUS CORP (CERS) reported annual revenue of $234 million in its most recent fiscal year, based on SEC EDGAR filings.
CERUS CORP (CERS) has a net profit margin of -6.7%. The company is currently unprofitable.
CERUS CORP (CERS) generated $1 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CERUS CORP (CERS) has a debt-to-equity ratio of 2.18. This indicates higher leverage, which may increase financial risk.
CERUS CORP (CERS) reported earnings per share (EPS) of $-0.08 in its most recent fiscal year.
CERUS CORP (CERS) has a return on equity (ROE) of -26.0%. A negative ROE may indicate losses or negative equity.
CERUS CORP (CERS) has a 5-year average gross margin of 46.4%. This indicates decent pricing power.
The Ledger Terminal provides 17 years of financial data for CERUS CORP (CERS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CERUS CORP (CERS) has a book value per share of $0.33, based on its most recent annual SEC filing.
No recent press releases.